|Positive WB detected in||HL-60 cells, PC-3 cells|
|Western Blot (WB)||WB : 1:200-1:1000|
|Sample-dependent, check data in validation data gallery|
15497-1-AP targets DR5-Specific in WB, ELISA applications and shows reactivity with human samples.
|Host / Isotype||Rabbit / IgG|
|Full Name||tumor necrosis factor receptor superfamily, member 10b|
|Calculated molecular weight||48 kDa|
|Observed molecular weight||58-60 kDa, 45-50 kDa, 32 kDa|
|GenBank accession number||NM_003842|
|Gene ID (NCBI)||8795|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.|
TNFRSF10B, also known as CD262, DR5, TRAILR2, TRICK2 and KILLER, is a widely expressed single-pass type I membrane protein belonging to the tumour necrosis factor receptor superfamily (TNFRSF). It is a receptor for TNF-related apoptosis-inducing ligand (TRAIL), which is a member of the tumor necrosis factor (TNF) family of cytokines and induces apoptosis in a wide variety of cells (PMID: 9311998). TNFRSF10B contains two extracellular cysteine-rich repeats, typical for TNF receptor (TNFR) family members, and a cytoplasmic death domain (DD), through which TNFRSF10B is capable to transmit the apoptotic signal (PMID: 9311998; 20531300). In PDAC cells, especially Panc89 cells, it expresses additionally to the approximately 48 and 40 kDa forms of DR5, a faster migrating variant of DR5 of about 32 kDa(PMID:20354842). The TRAIL receptor 2 (death receptor 5, or DR5) forms receptor dimers in a ligand-dependent manner, and these receptor dimers exist within high molecular weight networks(Dr. Jonathan N. Sachs,2012).
A non-canonical pathway regulates ER stress signaling and blocks ER stress-induced apoptosis and heart failure.
Int J Biol Sci
ESRG is critical to maintain the cell survival and self-renewal/pluripotency of hPSCs by collaborating with MCM2 to suppress p53 pathway
Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
A small-molecule Skp1 inhibitor elicits cell death by p53-dependent mechanism.
Discovery and characterization of 4-hydroxy-2-pyridone derivative sambutoxin as a potent and promising anticancer drug candidate: activity and molecular mechanism.
Arch Biochem Biophys
Luteolin enhances TRAIL sensitivity in non-small cell lung cancer cells through increasing DR5 expression and Drp1-mediated mitochondrial fission.